Skip to main content

Advertisement

SpringerLink
Log in

Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

AE:

Adverse event

ALT:

Alanine aminotransferase

AP:

Alkaline phosphatase

AST:

Aspartate aminotransferase

CTLA-4:

Cytotoxic T-lymphocyte antigen-4

ULN:

Upper limit of normal

References

  1. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275–5283.

    Article  PubMed  CAS  Google Scholar 

  2. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2–9.

    Article  PubMed  CAS  Google Scholar 

  3. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–5598.

    Article  PubMed  CAS  Google Scholar 

  4. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–164.

    Article  PubMed  CAS  Google Scholar 

  5. O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm phase II study. Ann Oncol. 2010;21:1712–1717.

    Article  PubMed  Google Scholar 

  6. Maio M, Lebbé C, Neyns B, et al. Three-Year Survival Rates for Patients with Advanced Melanoma Who Received Ipilimumab at 10 mg/kg in Phase II Trials [Abstract]. In: Presented at the XIV annual meeting of the perspectives in melanoma, 2010 September 17–18, Amsterdam, The Netherlands. 2010.

  7. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.

    Article  PubMed  CAS  Google Scholar 

  8. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526. doi:10.1056/NEJMoa1104621.

    Google Scholar 

  9. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864–872.

    Article  PubMed  CAS  Google Scholar 

  10. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533–546.

    Article  PubMed  CAS  Google Scholar 

  11. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockades in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–8377.

    Article  PubMed  CAS  Google Scholar 

  12. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.

    Article  PubMed  CAS  Google Scholar 

  13. Qiu D, Wang Q, Wang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol. 2011;54:340–347.

    Article  PubMed  Google Scholar 

  14. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver Injury. Clin Pharmacol Ther. 2011;89:806–815.

    Article  PubMed  CAS  Google Scholar 

  15. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–976.

    Article  PubMed  CAS  Google Scholar 

  16. Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin Diagn Pathol. 2006;23:132–148.

    Article  PubMed  Google Scholar 

  17. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–2769.

    Article  PubMed  CAS  Google Scholar 

  18. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54–66.

    Article  PubMed  CAS  Google Scholar 

  19. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–939.

    Article  PubMed  Google Scholar 

  20. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11–21.

    PubMed  Google Scholar 

  21. Sulz MC, Gerlach TJ. Autoimmune hepatitis. Ther Umsch. 2011;68:189–194.

    Article  PubMed  Google Scholar 

  22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Editorial and writing assistance was provided by StemScientific, funded by Bristol-Myers Squibb Co. This research was supported in part by the Intramural Research Program of the US National Institutes of Health (National Cancer Institute).

Conflict of interest

David E. Kleiner: No financial, professional or personal conflicts of interest exist with respect to this work. David Berman is an employee of Bristol-Myers Squibb Company and discloses ownership of equity in the company.

Author information

Authors and Affiliations

  1. Laboratory of Pathology, National Cancer Institute, Bldg 10, Room 2B50, MSC 1500, 10 Center Drive, Bethesda, MD, 20892, USA

    David E. Kleiner

  2. Research and Development–Global Clinical Research, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ, 08543, USA

    David Berman

Authors
  1. David E. Kleiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Berman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David E. Kleiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kleiner, D.E., Berman, D. Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma. Dig Dis Sci 57, 2233–2240 (2012). https://doi.org/10.1007/s10620-012-2140-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2140-5

Keywords

Search

Navigation